Hosted on MSN2mon
Novo Nordisk stock price takes a tumble after the Wegovy maker’s next-generation weight-loss drug underwhelmsThe test drug combines semaglutide, the active ingredient in its blockbuster Wegovy, with cagrilintide, a dual approach that suppresses the appetite and manages how the body processes food.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback